Clinical Reviews in Allergy & Immunology

, Volume 29, Issue 1, pp 3–16

Omalizumab in asthma

Approval and postapproval experience

DOI: 10.1385/CRIAI:29:1:003

Cite this article as:
Chiang, D.T., Clark, J. & Casale, T.B. Clinic Rev Allerg Immunol (2005) 29: 3. doi:10.1385/CRIAI:29:1:003


Omalizumab is a humanized mouse monoclonal antibody that binds specificially to the constant region of the immunoglobulin (Ig)E heavy chain. Omalizumab exerts its effects by reducing free serum IgE levels and FcɛRI expression on several cell types. These effects have been shown to result in decreased airway inflammation and clinical improvement. In multiple studies, omalizumab has been shown to be efficacious in the treatment of moderate-to-severe persistent asthma and is currently approved by the US Food and Drug Administration for the treatment of moderate-to-severe allergic asthma in patients age 12 yr and older. Moreover, omalizumab has been demonstrated to be effective in the treatment of children and adults with seasonal and perennial allergic rhinitis. Postmarketing surveillance has shown omalizumab to be a relatively safe and well-tolerated medication.

Index Entries


Copyright information

© Humana Press Inc 2005

Authors and Affiliations

  • Dean T. Chiang
    • 1
  • Justin Clark
    • 1
  • Thomas B. Casale
    • 1
  1. 1.Division of Allergy and ImmunologyCreighton University Medical CenterOmaha